Table 1. Baseline Characteristics of the Patients.
| Variable | No. of patients (%) |
|---|---|
| Gender | |
| Male | 97 (75.2) |
| Female | 32 (24.8) |
| Age | |
| ≤ 50 | 82 (63.6) |
| >50 | 47 (36.4) |
| T classification | |
| T1 | 4 (3.1) |
| T2 | 26 (20.2) |
| T3 | 70 (54.3) |
| T4 | 29 (22.5) |
| N classification | |
| N0 | 14 (10.9) |
| N1 | 50 (38.8) |
| N2 | 60 (46.5) |
| N3 | 5 (3.9) |
| Clinical stage | |
| II | 7 (5.4) |
| III | 89 (69.0) |
| IVa/b | 33 (25.6) |
| Histological type | |
| WHO type II | 8 (6.2) |
| WHO type III | 121 (93.8) |
| EBV VCA/IgA | |
| Negative | 2 (1.6) |
| Positive ≤1:160 | 46 (36.5) |
| >1:160 | 78 (61.9) |
| EBV EA/IgA | |
| Negative | 17 (13.5) |
| Positive ≤1:20 | 44 (34.9) |
| >1:20 | 65 (51.6) |
| Treatment strategy | |
| ICa + RTb | 70 (54.3) |
| CCRTc +ICa | 36 (27.9) |
| CCRTc only | 23 (17.8) |
| Vital status (at follow-up) | |
| Alive | 79 (61.2) |
| Death | 50 (38.8) |
| Expression of XPA | |
| Low expression | 55 (42.6) |
| High expression | 74 (57.4) |
Note: a. IC, induction chemotherapy. b. RT, radiotherapy. c. CCRT, concurrent chemoradiotherapy.